Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Verastem Inc VSTM

Healthcare Biotechnology
Verastem, Inc. is a late-stage development biopharmaceutical company. The Company's pipeline is focused on anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) inhibition and focal adhesion kinase (FAK) inhibition. The Company’s advanced... see more

Recent & Breaking News (NDAQ:VSTM)

Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer

Business Wire April 18, 2024

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire April 4, 2024

Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer

Business Wire March 18, 2024

Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates

Business Wire March 14, 2024

Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women's Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs

Business Wire March 11, 2024

Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Business Wire March 5, 2024

Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024

Business Wire March 5, 2024

Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers

Business Wire January 29, 2024

Verastem Oncology Granted Fast Track Designation for Combination of Avutometinib and Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)

Business Wire January 18, 2024

Verastem Oncology to Participate in the B. Riley Securities 4th Annual Oncology Conference

Business Wire January 11, 2024

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire January 5, 2024

Verastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet Therapeutics

Business Wire December 18, 2023

Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Business Wire December 13, 2023

New Healthcare Professional Component of Let's Talk About LGSOC to Raise Awareness of Low-Grade Serous Ovarian Cancer as a Distinct and Different Form of Ovarian Cancer Requiring Tailored Resources and Treatment Approach

Business Wire November 13, 2023

Verastem Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Business Wire November 8, 2023

First-Of-Its-Kind, Multi-National Patient Impact Survey Reveals Unique Challenges and Gaps in Care for Patients with Low-Grade Serous Ovarian Cancer

Business Wire November 7, 2023

Verastem Oncology Announces Efficacy and Safety Data of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in Heavily Pretreated Patient Population

Business Wire November 6, 2023

Verastem Oncology Strengthens Executive Leadership Team with Key Appointments

Business Wire October 26, 2023

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire October 18, 2023

Verastem Oncology Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS(TM) (sotorasib) in KRAS G12C-Mutant Non-Small Cell Lung Cancer

Business Wire October 14, 2023